Abstract
One of the main challenges in the fight against HIV infection is to develop strategies that are able to eliminate the persistent viral reservoir that harbours integrated, replication-competent provirus within host cellular DNA. This reservoir is resistant to antiretroviral therapy (ART) and to clearance by the immune system of the host; viruses originating from this reservoir lead to rebound viraemia once treatment is stopped, giving rise to new rounds of infection. Several studies have focused on elucidating the cells and tissues that harbour persistent virus, the true size of the reservoir and how best to target it, but these topics are the subject of ongoing debate. In this Viewpoint article, several experts in the field discuss the constitution of the viral reservoir, how best to measure it and the best ways to target this source of persistent infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Soriano-Sarabia, N. et al. Peripheral Vγ9Vδ2 T cells are a novel reservoir of latent HIV infection. PLoS Pathog. 11, e1005201 (2015).
Churchill, M. J. et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J. Neurovirol. 12, 146–152 (2006).
Johnson, T. P. et al. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc. Natl Acad. Sci. USA 110, 13588–13593 (2013).
Canestri, A. et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 50, 773–778 (2010).
Dahl, V. et al. An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J. Infect. Dis. 209, 1618–1622 (2014).
Peluso, M. J. et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 26, 1765–1774 (2012).
Crooks, A. M. et al. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. 212, 1361–1365 (2015).
Churchill, M. J. et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 66, 253–258 (2009).
Glass, J. D., Fedor, H., Wesselingh, S. L., McArthur, J. C. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 38, 755–762 (1995).
Gray, L. R. et al. CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2015.111, (2015).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Churchill, M., Deeks, S., Margolis, D. et al. HIV reservoirs: what, where and how to target them. Nat Rev Microbiol 14, 55–60 (2016). https://doi.org/10.1038/nrmicro.2015.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrmicro.2015.5
This article is cited by
-
HIV-1 mRNA knockdown with CRISPR/CAS9 enhances neurocognitive function
Journal of NeuroVirology (2024)
-
Tenofovir-tethered gold nanoparticles as a novel multifunctional long-acting anti-HIV therapy to overcome deficient drug delivery-: an in vivo proof of concept
Journal of Nanobiotechnology (2023)
-
Chronic brain damage in HIV-infected individuals under antiretroviral therapy is associated with viral reservoirs, sulfatide release, and compromised cell-to-cell communication
Cellular and Molecular Life Sciences (2023)
-
Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV
Journal of Neuroimmune Pharmacology (2023)
-
S100A8-mediated metabolic adaptation controls HIV-1 persistence in macrophages in vivo
Nature Communications (2022)